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ABSTRACT
Purpose Amyloid β (Aβ) drives the accumulation of excess
Phosphatase and Tensin Homolog Deleted on Chromosome
10 (PTEN) at synapses, inducing synaptic depression and per-
turbing memory. This recruitment of PTEN to synapses in
response to Aβ drives its interaction with PSD95/Disc
large/Zonula occludens-1 (PDZ) proteins and, indeed, we
previously showed that an oligo lipopeptide (PTEN-PDZ) ca-
pable of blocking such PTEN:PDZ interactions rescues the
synaptic and cognitive deficits in a mouse model of
Alzheimer’s disease. Hence, the PTEN:PDZ interaction
appears to be crucial for Aβ-induced synaptic and cognitive
impairment. Here we have evaluated the feasibility of using
PTEN-PDZ lipopeptides based on the human/mouse PTEN
C-terminal sequence, testing their stability in biological fluids,
their cytotoxicity, their ability to self-assemble and their in vitro
blood-brain barrier (BBB) permeability. Myristoyl or Lauryl
tails were added to the peptides to enhance their cell
permeability.
Methods Lipopeptides self assembly was assessed using elec-
tron microscopy and the thioflavin T assay. Stability studies in
mouse plasma (50%), intestinal washing, brain and liver
homogenates as well as permeability studies across an all hu-
man 2D blood-brain barrier model prepared with human
cerebral endothelial cells (hCMEC/D3) and human astro-
cytes (SC-1800) were undertaken.
Results The mouse lauryl peptide displayed enhanced overall
stability in plasma, ensuring a longer half-life in circulation
that meant there were larger amounts available for transport
across the BBB (Papp0-4h: 6.28 ± 1.85 × 10
−6 cm s−1).
Conclusion This increased availability, coupled to adequate
BBB permeability, makes this peptide a good candidate for
therapeutic parenteral (intravenous, intramuscular) adminis-
tration and nose-to-brain delivery.
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INTRODUCTION
Peptides play essential roles in human physiology, acting as
hormones, growth factors, neurotransmitters and, antibacte-
rial agents, and their pharmacological characteristics define
their strengths and weaknesses as potential drugs. In recent
years, peptides have generated increasing interest in the scien-
tific community, and they have been implemented in drug
discovery programs by the pharmaceutical industry (1–4).
Indeed, the role that peptide therapies can play in addressing
unmet medical needs has been recognized, as has their poten-
tial to complement or surpass alternatives like small molecules
and biological drugs (1). Like other protein-based therapeutic
agents such as antibodies, peptides are generally very specific,
and they are more likely to be sufficiently stable and perme-
able when used via non-invasive routes (5). In the case of
Alzheimer’s disease (AD), the symptomatic therapies or
disease-modifying agents available are on the whole unsatis-
factory, and the number of drugs approved for human use has
been limited by a high rate of failure of lead compounds in
clinical trials (6).
Many approaches to treat AD have focused on lowering
the levels of beta-amyloid (Aβ) in the brain but to date, most
have been unsuccessful with the sole exception of aducanu-
mab, an anti-amyloid antibody that reduces Aβ levels in the
brain and that slows the rate of cognitive decline in individuals
with mild or preclinical AD (6). However, the efficacy of this
antibody in Phase III clinical trials has yet to be confirmed.
Soluble Aβ assemblies directly alter synaptic plasticity by
inhibiting long-term potentiation (LTP) and facilitating long-
term depression (LTD) in hippocampal neurons (7), shifting
the balance of synaptic plasticity towards a pathologically en-
hanced form of depression. We were recently encouraged by
the discovery of a new approach to prevent memory loss in a
mouse model of AD that does not target Aβ but rather, that
focuses on preventing synaptic depression (7).
The lipid Phosphatase and Tensin Homolog Deleted on
Chromosome 10 (PTEN) and phosphatidylinositol-3-kinase
(PI3K) are essential regulators of excitatory synaptic structure
and function, modulating the activity of phosphatidylinosi-
tol-(3,4,5)-triphosphate (PIP3) (8–11). The activity of PI3K in
this pathway favors the formation of the PIP3 required for
AMPA receptor (AMPAR) activity at synapses (12). By con-
trast, PTEN dephosphorylates PIP3 and favors AMPAR en-
docytosis during LTD. We found that PTEN is recruited to
synapses during physiological LTD (13), and our latest data
indicated that this process is enhanced in the presence of Aβ
overload (7).
The participation of PTEN in LTD (13) strengthens the
notion that Aβ acts, at least partially, by taking over physio-
logical mechanisms of synaptic depression. Indeed, Aβ drives
excess PTEN accumulation at synapses, and this induces syn-
aptic depression and perturbs memory. Apart from PTEN,
Aβ triggers the recruitment of other effectors of the PIP3 path-
way into the postsynaptic compartment (e.g., Akt and
GSK3β), which is accompanied by a downregulation of the
PIP3 pathway in the dendritic spines (7,14). While the molec-
ular mechanisms controlling this phenomenon are unknown,
NMDAR (NMDA receptor) activation is required, as is an
interaction between PTEN and synaptic proteins (7).
Specifically, the recruitment of PTEN to synapses in response
to Aβ drives its interaction with PSD95/Disc large/Zonula
occludens-1 (PDZ) proteins. When this PTEN:PDZ interac-
tion is prevented, as in PTENΔPDZ mice in which PTEN lacks
its C-terminal PDZ motif (-QITKV), normal basal synaptic
transmission of neurons and LTP persists in the presence of
Aβ (7). This finding suggests that the PTEN:PDZ interaction
is crucial for Aβ-induced synaptic depression.
Based on this synaptic dysfunction triggered by Aβ, we
suggest that therapeutic strategies that focus on inhibiting
the PTEN:PDZ interactions may be potentially beneficial
interventions in conditions of Aβ overload. Therefore, we
designed a lipopeptide that corresponds to the last eight amino
acids of rat/mouse PTEN, with an added myristic acid to
augment its cell permeability (N-myristoyl-QHSQITKV -
“Myr-PTEN-PDZ”). This compound interacts with several
PDZ domains, of which the PDZ1+ 2 domains of PSD-95
are those most relevant to us, given that the PTEN-PSD-95
interaction is essential for the expression of LTD (13). Myr-
PTEN-PDZ saturates the PDZ interaction sites of PTEN,
thereby preventing PTEN from anchoring to PDZ proteins
and impeding LTD. The inability of synapses to expresses
LTD in the presence of Myr-PTEN-PDZ renders them resis-
tant to Aβ-induced synaptic depression (7). Following direct
administration of the Myr-PTEN-PDZ peptide into the cere-
bral ventricles of mice, the synaptic activity usually associated
with Aβ overload and cognitive impairment was reversed (7).
Hence, PTEN-PDZ peptides may represent pharmacological
tools that, by saturating PTEN:PDZ interaction sites, effec-
tively protect synapses from the deleterious effects of Aβ, pre-
venting cognitive deterioration.
These discoveries provide us with a new mechanism-based
therapeutic target to counteract signaling downstream of Aβ.
As such, novel pharmacological interventions can be directed
at modulating the interactions of PTEN with PDZ proteins,
thereby preventing pathological LTD. We hypothesize that
PTEN-PDZ peptides may impede or delay the onset of mem-
ory defects in the early phases of AD. Therefore, we used our
mouse Myr-PTEN-PDZ as a prototype to develop other sim-
ilar lipopeptides. Specifically, we replaced the myristoyl group
with a lauryl group for both the corresponding mouse/rat and
human sequences (N-Lauryl-QHSQITKV and N-Lauryl-
QHTQITKV, respectively). Lipidized peptides are more sta-
ble in biological fluids (7,15) and they display better perme-
ability across biological membranes like the blood-brain bar-
rier (BBB) (2,5), the intestinal mucosa (3,16,17) and the nasal
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mucosa (18). Here we assess the stability of the lipopeptides
developed in biological fluids relevant to parenteral routes
(50% v/v plasma, 50% w/v liver, and 50% w/v brain homo-
genates), as well as in a simulated intestinal fluid (SIF) that is
relevant to non-invasive routes. We also analyzed the cytotox-
icity of the lipopeptides towards human immortalised cerebral
endothelial capillary cells and their permeability across a hu-
man 2D BBB model, with a view to identifying PTEN-PDZ
lipopeptides ideal for preclinical development and administra-
tion via a minimally invasive route. Accordingly, N-lauryl-
QHSQITKV (mouse Lau-PTEN-PDZ) appears to be the
leading candidate for further development as AD therapies
administered via parenteral routes. These results represent
the first and the critical step in the discovery, design, and
subsequent development of novel therapeutics to combat
memory loss in AD.
MATERIALS AND METHODS
Materials
Different peptides were synthesized by CASLO Laboratory
ApS (Lyngby, Denmark), ≥98% pure by HPLC (Fig. 1): N-
Lauryl-QHSQITKV (mouse Lau-PTEN-PDZ); N-Lauryl-
QHTQITKV (human Lau-PTEN-PDZ); N-myristoyl-
QHSQITKV (mouse Myr-PTEN-PDZ), N-myristoyl-
QHTQITKV (human Myr-PTEN-PDZ). Other reagents
were obtained from Sigma Aldrich (Gillingham, UK): diaze-
pam (>98%), fluorescein isothiocyanate dextran (FITC-
Dextran, 3-5KDa, ≥90%), human serum (heat-inactivated
from human male AB plasma, sterile-filtered, USA origin),
human fibronectin, Bradford reagent, bovine serum albumin
(>98%, BSA), thioflavin T, and HPLC grade solvents (aceto-
nitrile, methanol). Fisher Scientific (UK) supplied the BD
Biosciences K3E EDTA vacutainers (evacuated, sterile,
spray-coated with 3.6 mg of tripotassium ethylenediaminete-
traacetic acid [EDTA], 3 × 75 mm medical-grade PET
tubes), dimethylsulfoxide (99.5%, DMSO, molecular biology
grade), trifluoroacetic acid (TFA, HPLC grade), sodium chlo-
ride (ACS grade), sterile-filtered Hank’s Balanced Salt
Solution (HBSS without calcium, magnesium, and phenol
red) and sterile-filtered Phosphate Buffered Saline (PBS, with-
out calcium and magnesium, pH 7.4). Human cerebral mi-
crovascular endothelial cells (hCMEC/D3, passage number
32–40), immortalized with a human telomerase reverse tran-
scriptase catalytic subunit, and a Simian vacuolating virus 40
(hTERT/SV40) cells were obtained from Dr. Pierre-Olivier
Courard (Institute Cochin, INSERM, Paris). The hCMEC/
D3 cells were cultured in endothelial basal medium-2 (EBM-
2) supplemented with the EGM-2 Bullet Kit (Lonza Ltd.,
Slough, UK). SC-1800 astrocytes (ScienCells research labora-
tories, Carlsbad, CA, USA) were grown in complete astrocyte
basal media (ABM™, CC-3187: Lonza Ltd., Slough, UK)
and AGM™ (CC-4123) supplemented with SingleQuots™
(Lonza Ltd., Slough, UK).
In Vitro Stability Studies in Mouse Plasma, Liver
and Brain Homogenates
CD-1 male mice (7 weeks old: Charles River Laboratories)
were sacrificed with CO2, and blood was collected in K3E
EDTA spray-coated vacutainers and kept on ice prior to cen-
trifugation at 3000 rpm for 15 min at 4°C (Heraeus Multifuge
3sf). Mouse plasma samples were stored at −80°C before use
in stability studies. Study was approved by the University of
Portsmouth Animal Welfare and Ethical Review Body (UoP
AWERB body, 817).
For testing, the plasma was diluted (1:1) in PBS without
phenol and pre-warmed to 37°C. Peptides stocks (5 mM in
DMSO) were prepared and maintained at −20°C before
performing the stability studies. Peptide stock solutions
(120 μL) were added to pre-warmed diluted plasma (50%
v/v, 1080 μL) and maintained at 37°C with agitation
(100 rpm: Grant Aqua Waterbath, Royston, UK). Samples
(80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180,
240, 360 and 1440 min, diluted with ice-cold acetonitrile
(80 μL), vortexed and left in −80°C at least overnight to favor
maximal protein precipitation. The samples were then vor-
texed again for 15 min (SciQuip microplate shaker,
Shropshire, UK), centrifuged in a Thermo Sci Jouan B4i
Centrifuge (Hemel Hampstead, UK) and the supernatant
was transferred to an HPLC vial (200 μL).
The samples were analyzed at 40°C on a Phenomenex
Lichrosorb RP8 C8 column (4.0 mm× 250 mm, 5 μm), using
the gradient elution method on an Agilent HPLC system
(Agilent Technologies, Cheadle, UK) equipped with an
1100 series degasser, quaternary pump, autosampler, and col-
umn heater, and attached to an Agilent 1200 series PDA
detector and a 1250 series fluorescent detector. The flow rate
was set at 1.2 mL min-1, and the injection volume was set at
40 μL, while detection was performed at 220 nm. The mobile
phase was a mixture of mobile phase A (0.1% TFA in water)
and phase B (0.08% TFA in acetonitrile), and in the first
5 min, the mobile phase was an 8:2 ratio of A:B (v/v) and from
5 to 15 min the percentage of B was raised from 8:2 to 1:9 (v/
v). Linear calibration curves were constructed for both pepti-
des between 0.1–100 μg.mL−1. The retention time for the
human Lau–PTEN-PDZ, mouse Lau–PTEN-PDZ, human
Myr–PTEN-PDZ, and mouse Myr–PTEN-PDZ was 12.03,
11.60, 13.68, and 13.91, respectively.
The liver and brain of the mice were excised from black
CD-1 male mice (7 weeks-old: Charles River Laboratories)
sacrificed with CO2, and the tissue was frozen immediately
with liquid nitrogen prior to storage at −80°C. The liver and
brain tissue were thawed and homogenized on ice in PBS
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(2 mL/g of tissue) using a glass 3 mL tissue homogenizer (20
strokes per sample), and the liver and brain homogenates were
centrifuged (Heraeus Multifuge 3sf, Fisher Scientific,
Basingstoke, UK) at 4300 g for 60 min at 4°C and at 3000 g
for 20 min at 4°C, respectively. The supernatant was stored at
−80°C, diluted 1:1 (v/v) with PBS (1x, pH 7.4), and used in
stability studies. Peptides stocks (5 mM in DMSO) were pre-
pared and maintained at −20°C prior to performing stability
studies. These stock solutions (120 μL) were added to the
diluted pre-warmed (37°C) liver or brain homogenate (50%
v/v, 1080 μL) with agitation (100 rpm: Grant Aqua
Waterbath), and samples (80 μL) were taken at 0, 5, 10, 15,
30, 45, 60, 90, 120, 180, 240, 360 and 1440 min, and diluted
with ice-cold acetonitrile (80 μL). Samples were vortexed and
left at −80°C at least overnight to allow for maximum protein
precipitation, the samples were vortexed again for 15 min,
centrifuged and the supernatant was analyzed by HPLC as
described above.
The total protein concentration in the homogenates was
determined using the Bradford protein assay (7,15) and BSA
as a standard. Ten stock solutions of BSA were prepared in
PBS between 0.1–1 mg mL−1, and 40 μL of each of the
diluted stocks were added to 1.2 mL of Bradford reagent
and incubated at room temperature for 5 min. The absor-
bance was recorded at 595 nm using a Multiskan GO spec-
trophotometer and the SkanIt software (Thermo Scientific,
Paisley, UK). A linear calibration curve was obtained in this
range that was used to extrapolate the protein content of
1:100 v/v stock solutions of 50% mouse plasma, liver, and
brain homogenates diluted in PBS.
In Vitro Stability Studies in Simulated Intestinal Fluid
(SIF)
The duodenum and ileum were excised from 10 non-fasted
CD-1 male mice (7 weeks-old: Charles River Laboratories)
that were sacrificed with CO2. Each duodenum and ileum
were washed with 6 ml of phosphate buffer (50 mM,
pH 6.63), and all the washes were pooled prior to centrifuga-
tion at 4000 rpm for 15 min at 4°C (Heraeus Multifuge 3sf)
(7,15). The intestinal wash was removed and frozen at −80°C
prior to using it in stability studies without further dilution.
Peptides stocks (5 mM in DMSO) were prepared and main-
tained at −20°C prior to performing stability studies. A stock
Fig. 1 A. Chemical structures of the PTEN-PDZ lipopeptides.
183 Page 4 of 13 Pharm Res (2020) 37: 183
peptide solution (120 μL) was added to the diluted pre-
warmed (37°C) intestinal wash (1080 μL) with agitation at
100 rpm (Grant Aqua Waterbath), and samples (80 μL) were
taken at 0, 15, 30, 45, 60, 90, 120, 180, 240, 360 and
1440 min, and diluted with ice-cold glacial acetic acid
(17.5 M): acetonitrile (5:95 v/v, 80 μL) to quench the enzyme
activity. Samples were vortexed and left in −80°C at least
overnight to maximize protein precipitation, and after vortex-
ing again for 15 min and centrifuging, the supernatant was
analyzed by HPLC as described above.
Critical Aggregation Concentration Studies
Thioflavin T, a probe that possesses freely rotatable dimethy-
laniline and benzothiazole ring around a shared bond, is used
to assess the self-assembly of amphiphilic peptides in aqueous
media. When immobilized in fibrils or aggregates, this probe
maintains an excited state, resulting in an increase in fluores-
cence. Peptide stock solutions (0.1–40,000 μM) were prepared
in DMSO and diluted 100-fold in PBS to yield solutions rang-
ing from 0.001–400 μM.Diluted stocks (20 μL) were added to
freshly prepared thioflavin T (50 μM, 80 μL) and incubated
for 5 min at room temperature, protected from the light. The
fluorescence of the solutions was thenmeasured at λex 450 nm
and λem 482 nm in black 96-well plates on a Synergy H1
microplate reader and with Gen 5 software (BioteK,
Vermont, USA). The critical aggregation concentration
(CAC) was calculated using the tangent method (19).
Morphology of the Aqueous Dispersion of Lipopeptides
Using Transmission Electron Microscopy (TEM)
TEM was used to study the morphology of the amphiphiles.
Peptide stock solutions (40,000 μM) were prepared in DMSO
and diluted 100-fold in PBS (Gibco 10,010–31, Lot:1930056)
to yield 400 μM solutions. These solutions were diluted 1:5 in
deionized water, and a drop of the diluted solution was placed
on the coated side of a copper Formvar/Carbon coated grid
(F196/100 3.05 mm, 300 mesh, TAAB, UK) and allowed to
dry for 5 min. The sample was then negatively stained with a
drop of 2% w/v uranyl acetate aqueous solution for 30 s. The
grid was blotted with Whatman No1 filter paper and allowed
to dry at room temperature. Images were analyzed on a JEM-
1400 electron microscope (Jeol, Herts, UK), and the images
were acquired with an AMT digital camera (Advanced
Microscopy Techniques, Suffolk, UK) (20).
Metabolic Assays in hCMEC/D3 Cells
HCMEC/D3 (passage number 32–40) cultured in EBM-2
(Lonza) supplemented with the EGM-2 Bullet Kit™
(Lonza), and 2% v/v human serum (Sigma H3667, Batch:
SLBW2276) were used to assess the cytotoxicity of lipidized
peptides. The cells were subjected to routine mycoplasma
testing and authenticated in house. The cells were seeded at
46,875 cells/cm2 in complete medium, and allowed to attach
overnight, refreshing the medium to treat the cells with pep-
tide solutions. The peptide solutions were prepared from 100-
fold DMSO stocks at a final concentration between 1 and
400 μM in complete medium to ensure a final DMSO con-
centration of 0.5%, and 200 μL of the diluted stock was added
to each well. The metabolic activity of the cells was measured
after 4 and 24 h using the MTT (3-(4,5)-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. At the time points
specified, the MTT solution was added to each well (20 μL
at 5 mg.mL−1 in PBS), and the cells were incubated for 4 h at
37°C. Subsequently, DMSO (100 μL) was added to dissolve
the formazan crystals, and the absorbance was measured at
570 and 690 nm on a Multiskan Go microplate spectropho-
tometer, analyzing the data using the SkanIt software
(Thermo Scientific, Paisley, UK). Cell metabolic activity was
calculated by subtracting the values at 690 nm from those at
570 nm to remove the background and dividing the values by
the control to express this value as a percentage (%) of the
control (0.5% DMSO).
Cell Metabolic Activity %ð Þ
¼ Abs570 nm Sample−Abs690 nm Sample
  100
Abs570 nm Control−Abs690 nm Controlð Þ ð1Þ
IC50 values were calculated using Graphpad Prism 8.0
(San Diego, USA) and fitted using a non-linear regression
model ([Inhibitor] vs. response (three parameters)).
Permeability Studies across an In Vitro 2D Human
Blood-Brain Barrier (BBB) Model
HCMEC/D3 were cultured in EBM-2 (Lonza) supplemented
with the EGM-2 Bullet Kit™ (Lonza) and 2% human serum
(v/v: Sigma H3667, Batch SLBW2276). A static in vitro co-
culture model was set up in 24-well Transwell polycarbonate
membranes (3 μm pore size, 0.33 cm2 area: Corning Costar,
Deeside, UK), the abluminal side coated for 1 h at room
temperature with fibronectin from human plasma (5 μg/cm2
in HBSS). SC-1800 astrocytes (25,000 cells in 100 μL) were
seeded onto the abluminal side in complete ABM (ABM™
Basal Medium, CC-3187, and AGM™ SingleQuots™
Supplements, CC-4123: Lonza) for astrocyte growth, and
they were allowed to attach for 2 h at room temperature.
The membranes were then flipped in the 24-well plates, and
the SC-1800 cells were grown for 3 days in complete ABM
media (600 μL and 200 μL on the luminal and abluminal side
of the Transwell respectively). After 3 days in culture, the
luminal side of the Transwell membranes was coated for 1 h
at 37°C with fibronectin from human plasma (5 μg/cm2 in
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HBSS). HCMEC/D3 were cultured as above and seeded
onto the luminal side of the membrane in 200 μL of complete
EBM-2 (75,000 cells per Transwell), and then co-cultured
with the astrocytes for 5 days. The medium on both sides of
the Transwell was changed daily, adding 600 μL of complete
ABM added to the abluminal side and 200 μL of complete
EBM-2 on the luminal side of the Transwell.
To evaluate the integrity of the barrier, the trans-
epithelial electrical resistance (TEER) was measured using
an EVOM volt ohmmeter (World Precision Instruments,
Berlin, Germany). All Transwells in a 24-well plate were
equilibrated at room temperature while the EVOM elec-
trodes were equilibrated in PBS (0.01 M, pH 7.4), giving a
TEER of ~0 Ω.cm2. Electrodes were inserted into the
wells at a 90o angle, and the cell resistance was recorded
in ohms (Ω). The resistance of a new membrane immersed
in PBS was recorded to obtain the real resistance of the co-
culture based on the following equation:
TEER ¼ TEER sample–TEER blankð Þ x Transwell Surface Area
ð2Þ
where the TEER of the blank Transwell was subtracted
from the TEER of the co-culture and multiplied by the
surface area of the membrane (0.33 cm2), giving the final
TEER in Ω.cm2.
After 5 days and when the TEER value reached the maxi-
mum resistance (25± 1.63Ω.cm2) due to tight junction matura-
tion, the Transwell inserts were washed with PBS (no phenol red)
and immersed in a fresh buffer (600 μL) placed on the abluminal
side. The peptides dissolved in DMSO were diluted 200-fold in
PBS and added to the luminal side of the Transwells (100 μM,
150 μL). Diazepam and FITC-dextran (3–5 kDa) were used as
controls for the permeability studies. Diazepam is a lipophilic
drug known to cross the BBB trans-cellularly (16), while FITC-
dextran is known to cross the BBB in a luminal to abluminal
direction paracellularly (21). Diazepam (150 μL, 50 μg mL−1
in PBS) and FITC-dextran (150 μL, 500 μg mL−1 in PBS) sol-
utions were added to the luminal side of the Transwell, and the
co-cultures were incubated at 37°C with agitation (150 rpm:
Heidolph Titramax 1000, Heidorph, Schwabach, Germany).
Samples (100 μL) were collected from the abluminal side at
specific time points and replaced with an equal volume of fresh
PBS. The samples were stored at −80°C for further analysis.
Peptides were analyzed by HPLC, as described above. All
diazepam samples were analyzed on a Phenomenex Hypersil
C18 CN column (150× 4.5 mm, 5 μm) and eluted isocratically
using an Agilent 1100 series RP-HPLC apparatus equipped with
a quaternary pump, autosampler, and photodiode array detector
(Agilent Technologies, Cheadle, UK). The mobile phase was
acetonitrile:methanol: phosphate buffer (20 mM, pH 2.37) at a
ratio of 27:10:63 v/v. Diazepam was eluted at a flow rate of
1.2 mL min−1 at room temperature, and the injection volume
was set at 40 μL, detecting the samples at 230 nm and analyzing
the results with OpenLAB software (Agilent Technologies,
Cheadle, UK). The retention time was 2.75 min, and a calibra-
tion curve of diazepam in the mobile phase was prepared from
0.025–100 μg mL−1 to extrapolate the concentration of diaze-
pam in the samples. The fluorescence of FITC-dextran samples
was analyzed on a POLARstar Omega Plate Reader spectro-
photometer (BMG LABTECH, Ortenberg, Germany), mea-
sured at λex 485 and λem 520 nm in black 96-well plates. A
calibration curve of FITC-dextran in PBS was prepared from
0.25–500μgmL−1 to quantify the FITCdextran concentrations.
The permeability coefficient (Papp) was determined using
the equation below:
Papp ¼ ΔQrΔt 
Vr
A  C0  60 ð3Þ
where ΔQr/Δt is the amount of compound in basal compart-
ment (μg mL−1) as a function of time (minutes), Vr is the
volume on the abluminal side (mL), A is the surface area of
the Transwell membrane, Co is the concentration of drug on
the luminal side, and 60 is the conversion factor from minutes
to seconds. Two experiments were carried out due to the
number of replicates possible per Transwell plate. Diazepam
was included in both experiments as a positive control.
RESULTS
We designed four “PTEN-PDZ” peptides based on the last eight
amino acids of the mouse/human PTEN, adding fatty acids
(myristoyl or lauryl groups) to augment their cell permeability
and stability. As part of our preclinical assessment of these four
lipidized synthetic peptides, we evaluated their plasma, brain,
liver, and gastrointestinal stability, their ability to self-assemble
in aqueous media, and their toxicity in human immortalised
cerebral endothelial cells, as well as their BBB permeability.
This information was used to consider the most likely intended
route of administration and to help select one of the synthetic
lipidized peptide analogs to use in further preclinical
development.
The Sequence and Fatty Acid Group Determine
the Stability
Ideally, an oral formulation for AD would revolutionize current
treatment options. The first hurdle that a peptide faces following
oral delivery are the high salt and acidic environment of the
stomach, which, when combined with the action of pepsin, can
denature the peptide. As little is known about the stability of the
peptides understudy in the gastrointestinal tract, we assessed their
stability in a soluble fraction of the digestive enzymes present in
the upper gastrointestinal tract, where the peptide must be
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released for absorption and where it is likely to be attacked by
proteolytic enzymes (15). This soluble fraction contains pancre-
atic proteases like trypsin and chymotrypsin, carboxypeptidases
and aminopeptidases that can hydrolyze peptides to di- or tripep-
tides (5). Our stability studies in a simulated intestinal fluid (SIF)
indicate that the prototypic mouseMyr-PTEN-PDZ lipopeptide
shows the best stability (Fig. 2a and Table I) and if oral delivery is
considered, this peptide will have an advantage in eliciting
the largest window for oral absorption, thereby resulting
in the highest oral bioavailability. Nevertheless, the in-
dustrial processes currently available for enteric coating
can easily overcome the hurdle if peptides are unstable
in the upper gastrointestinal tract (5).
The clearance of therapeutic peptides is very dependent on
the intense metabolism by liver enzymes, which can degrade
all the peptide that reaches the bloodstream after intravenous,
or other parenteral and non-invasive (oral and nasal) routes of
administration, within minutes (22). Peptides with good plas-
ma and liver stability are more likely to remain in circulation.
If the peptide permeates the BBB, higher levels will reach the
brain after invasive and non-invasive administration. The
mouse Myr-PTEN-PDZ demonstrated the highest liver sta-
bility (Fig. 2b and Table I).
Themouse PTEN-PDZ lipidized peptides (Myr/Lau) were
more stable in murine plasma (50% v/v), exhibiting longer
half-lives than the human peptides and with more than 50%
of the peptide remaining after a 2-h incubation (Fig. 2c-d,
Table I). These longer mouse plasma half-lives can be
explained by differences in protein binding between the two
species (23,24). Based on the higher lipophilicity of the myr-
istoylated peptides, lauryl peptides are expected to bind less
protein (1). Lipopeptides can permeate via both active and
passive processes across the BBB. The free peptide fraction
will be available for transport transcellularly, while protein
binding to certain plasma proteins can induce receptor medi-
ated uptake across the BBB. Thus, laurylated peptides are
expected to be more available for transcellular transport,
while more mechanistic studies are needed to elucidate the
mechanism of BBB permeation and the biological effect of
protein binding of these lipopeptides. Based on the above,
the mouse Lau-PTEN-PDZ peptide, showing good stability
in mouse plasma and a half-life of 5.9 h (Table I), would
Fig. 2 The proportion of the peptide remaining after incubation in 50% v/v plasma, 50% w/v brain homogenate, 50% w/v liver homogenate, or simulated
intestinal fluid (SIF). The data are presented as the means ± SEM (n=3). The protein content was quantified using the Bradford assay and the protein content of
50% v/v plasma, 50% w/v brain homogenate, 50% w/v liver homogenates, and SIF was 8.71± 0.30, 8.01± 0.75, 60.42± 6.81 and 1.05± 0.21 mg mL−1
respectively.
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appear to be a good candidate for further development via
parenteral routes. Lastly, all four peptides show good in vitro
brain homogenate stability with the human Lau-PTEN-PDZ,
and mouse Myr-PTEN-PDZ demonstrated better stability
than the other peptides (Fig. 2d and Table I).
Self-Assembly of Lipidized Peptides in Micromolar
Concentrations
Although small peptides typically adopt flexible conforma-
tions in aqueous media, lipopeptides have a more stable
structure due to their ability to self-assemble into oligomers
or larger aggregates of varied morphologies (i.e., spherical,
long-axial, tapes or ribbons). Self-assembly of peptide
amphiphiles is driven by gains in entropy. Such gains are
associated with the dehydration of hydrophobic moieties
and the resulting hydrophobic associations as the water
molecules adjacent to the hydrophobic part of the peptide
are forced to assume a higher-ordered structure, and they
become unable to hydrogen bond freely. This gain in en-
tropy by the water molecules is what ultimately drives the
process of self-assembly (25). These stabilized structures
can be manipulated to enhance their resistance to enzy-
matic degradation. We used the thioflavin T assay to cal-
culate the aggregation concentrations of the lipopeptides.
Mouse peptides had close to a 4-fold lower critical aggre-
gation concentrations (CACs), in the micromolar range
(Fig. 3). As expected from the tail length and critical pack-
ing parameter (25,26), the myristoylated peptides assemble
at 20-fold lower CACs than the laurylated peptides. The
formation of spherical oligomers would be expected due to
the use of a saturated linear hydrophobic tail less than 16
carbons in length, as shown by TEM of mouse Myr-
PTEN-PDZ. The formation of small spherical oligomers
might explain their enhanced stability in biological media
and, to some extent, the enhanced stability of the murine
PTEN-PDZ peptides.
Cell Treated with the Mouse Myr-PTEN-PDZ Shows
Cytotoxicity
The toxicity of the peptides to hCMEC/D3 cells was assessed
prior to testing them in our in vitro BBB model to ensure that
they were well tolerated at the concentrations used. TheMTT
assay demonstrated acute toxicity of hCMEC/D3 cells to the
peptides after 4 h, yet these cells recovered at 24 h. Indeed,
more than 80% of the cells remained metabolically active
when exposed to the peptides at a concentration of 200 μM
that was intended to be used in the BBB permeability assays
(Fig. 4). However, this was not the case for the mouse Myr-
Table I Summary of the half-livesof the peptides
Peptide Equation fitted k (h−1) t1/2 (h) / t1/2 (min) r
2
Simulated intestinal fluid
Human Lau-PTEN-PDZ One phase decay, Least square fit 0.23 2.96 / 177.96 0.22
Mouse Lau- PTEN-PDZ One phase decay, Least square fit 2.34 0.30 / 17.77 0.47
Human Myr-PTEN-PDZ One phase decay, Least square fit 0.25 Could not be calculated
due to fitting (deviation)
0.12
Mouse Myr-PTEN-PDZ One phase decay, Least square fit 0.15 4.52/ 271.02 0.74
50% w/v Liver Homogenate
Human Lau-PTEN-PDZ One phase decay, Least square fit 1.15 0.60 / 36.28 0.79
Mouse Lau- PTEN-PDZ One phase decay, Least square fit 0.73 0.95 / 57.14 0.75
Human Myr-PTEN-PDZ One phase decay, Least square fit 0.04 18.5 / 1110 0.49
Two phase decay 3.05 (fast), 0.0005 (slow) 0.23 (fast) & 1510 (slow) /
13.63 (fast) & 90,600 (slow)
0.54
Mouse Myr-PTEN-PDZ One phase decay, Least square fit 0.51 1.36/ 81.66 0.85
50% v/v Plasma (Mouse)
Human Lau-PTEN-PDZ One phase decay, Least square fit 4.60 0.15 / 9.05 0.83
Mouse Lau- PTEN-PDZ One phase decay, Least square fit 0.12 5.86 / 351.84 0.60
Human Myr-PTEN-PDZ One phase decay, Least square fit 6.17 0.11/ 6.74 0.57
Mouse Myr-PTEN-PDZ One phase decay, Least square fit 0.80 0.87/ 52.16 0.17
50% w/v Brain Homogenate
Human Lau-PTEN-PDZ One phase decay, Least square fit 1.90 0.36 / 21.87 0.88
Mouse Lau- PTEN-PDZ One phase decay, Least square fit 3.48 0.20 / 11.95 0.84
Human Myr-PTEN-PDZ One phase decay, Least square fit 4.20 0.16 / 9.89 0.61
Mouse Myr-PTEN-PDZ One phase decay, Least square fit 2.71 0.25 / 15.32 0.78
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PTEN-PDZ, the only peptide that did not allow the cells to
recover after 24 h.
Laurylated Peptides Are Permeable across the BBB
As the BBB protects the brain from unwanted chemicals in the
blood, it may hinder the passage of therapeutic compounds to
the brain (27,28). Nonetheless, lipid-mediated transport favors
the passage of lipid-soluble small molecules, below a 400–
600 Da threshold, across the BBB (29). Thus, in addition to
selecting compounds with a strong potential for BBB trans-
port, we employed an all human 2D in vitro BBB Transwell
model (30,31) to test their penetration through a model of the
BBB comprised by human immoralised brain capillary endo-
thelial cells (hCMEC/D3) and SC-1800 astrocytes in the
blood-to-brain direction. The passage of each molecule from
the ‘blood’ compartment of a single insert across the barrier
was measured at multiple time points, detecting the amount of
Fig. 3 (a) Top: Thioflavin Tstructure; Bottom: TEM images of mouse Myr-PTEN-PDZ supramolecular structures (2% Uranyl acetate staining, scale bar = 50
and 20 nm). (b-e) Thioflavin Taggregation assay of peptide oligomers (b: Human Lau-PTEN-PDZ, c: Mouse Lau-PTEN-PDZ, d: Human Myr-PTEN-PDZ, e:
Mouse Myr-PTEN-PDZ) (n = 3).
Fig. 4 Cell metabolic activity (%) in hCMEC/D3 cells versus log concentration of the peptides after a 4-h (left) and 24-h (right) exposure. Data are normalized as
% control using GraphPad Prism 8.02 and presented as means ± SEM (n =3).
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the peptide in the ‘brain’ compartment and calculating the
apparent permeability coefficient (Papp) for all the peptides.
Lauryl peptides were almost twice as permeable across the
BBB than the myristoylated peptides, with the mouse Lau-
PTEN-PDZ demonstrating the highest permeability (6.3 ±
1.8 × 10−6 cm/s, Table II). The Papp values calculated for
the controls (FITC-dextran and diazepam) were similar to
those reported previously (16,21,32,33), with typical values
for FITC-dextran ranging between 0.2–7.3 × 10−6 cm s−1,
further evidence of the validity of our model (34).
Significantly, the Papp for the mouse Lau-PTEN-PDZ pep-
tide was in the same range as that reported for brain perme-
able peptides like Angiopep-2 Papp, 8.69 ± 1.53 × 10−6 cm/s
(35).
DISCUSSION
We have analyzed here the possible clinical utility of four
PTEN-PDZ lipopeptides by testing their stability in biological
fluids, their cytotoxicity, their ability to self-assemble, and their
BBB permeability. Using the mouse Myr-PTEN-PDZ as a
prototype, we developed three similar lipopeptides based on
the human/mouse PTENC-terminal sequence. We set out to
determine which one of these potential drugs would be the
most suitable agent for preclinical development as a novel
therapeutic agent to combat memory loss in AD.
Therapeutic peptides generally have poor oral bioavail-
ability (injection is usually required), and their capacity to
cross the BBB is limited, resulting in high production costs.
The oral-systemic availability of a peptide (F) is determined by
the fraction of the dose that is not lost to the feces or metab-
olized in the gut (FF). The fraction that escapes degradation at
the wall of the gastrointestinal tract to reach the portal vein
(FG) and that which escapes liver metabolism also determines
the oral-systemic availability of peptides (FH), whereby
F=FF*FG*FH (36). Based on the amino acid sequence of the
peptides we tested, they are likely to be degraded mainly by
pancreatic proteases, such as trypsin (at Lys2) and chymotryp-
sin (at His7). A minimally invasive or oral therapy for AD
could revolutionize treatment options for AD patients even
though this route of administration minimizes the efficiency
and potency of potential drug therapies (37). Our stability
studies in a SIF that contains pancreatic proteases, among
the soluble enzymes present in the gastrointestinal tract, indi-
cate that the prototypic mouse Myr-PTEN-PDZ lipopeptide
and possibly the derived human Lau-PTEN-PDZ might be
suitable candidates for oral delivery. Nevertheless, the former
has lower plasma stability to human Lau-PTEN-PDZ, but the
latter exhibits low liver stability. Thus, it seems that another
minimally invasive route, either parenteral or nasal, is likely to
yield higher brain levels of these peptides and produce a better
therapeutic response, with a minimal dose and lower cost.
We report here that while the mouse Myr-PTEN-PDZ
peptide shows acceptable stability in most of the biological
fluids (Table III), its BBB permeability is low compared to
the other peptides, and it shows a high cytotoxicity rate. The
human Myr-PTEN-PDZ peptide shows low stability in plas-
ma and a relatively low BBB permeability. On the other hand,
the human Lau-PTEN-PDZ shows good stability in most bi-
ological fluids, a good BBB permeability, and less cytotoxicity.
The mouse Lau-PTEN-PDZ, followed by the human Lau-
PTEN-PDZ peptide, represents the least toxic of the peptides
for human immortalized cerebral endothelial cells, which con-
stitute the luminal side of the BBB. The mouse Lau-PTEN-
PDZ peptide shows good stability inmouse plasma, good BBB
permeability, and low cytotoxicity.Moreover, these two deriv-
atives are the leading candidates for delivery via minimally
invasive routes (intramuscular, subcutaneous, and nasal) due
to their enhanced permeability across a 2D human BBBmod-
el. Nevertheless, human Lau-PTEN-PDZ is not very stable in
mouse plasma (50%), and therefore, it is less suitable for pre-
clinical research. Only the mouse Lau-PTEN-PDZ has both
good BBB permeability and plasma stability. At the same
time, this peptide is likely to bind less protein as it is less lipo-
philic. A long plasma half-life is essential to elicit an effective
brain response. Intravenous, subcutaneous, intramuscular,
and nasal delivery are potential routes for these peptides.
The increased stability of peptides in biological media can
be attributed to their amphiphilic character and to their abil-
ity to self-assemble in aqueous media in micromolar concen-
trations. Serine endopeptidases or threonine endopeptidases
are enzymes likely to be involved in the plasma, and tissue
degradation of these peptides, as well as proteinase K.
Previous studies showed that in terms of permeability across
Caco-2 cells, lipidation with a shorter C8 tail is more beneficial
than a C12 tail for amine-modified peptides (38), although we
do not know if this is the case for these peptides. Even if the
permeability of shorter tail lipopeptides is high, if they are not
stable in the gastrointestinal tract, their oral bioavailability
in vivo will be limited. Finally, liver stability and permeability
across the BBB needs to be taken into consideration, and
taking all factors together, mouse myristoylated peptides
appeared to be the best candidate of the lipopeptides tested
for oral development.
The stability data so far indicate that mouse Lau-PTEN-
PDZ was more stable in plasma (50% v/v), ensuring a longer
half-life in circulation and allowing more of the peptide to be
transported across the BBB and would make it a good candi-
date for parenteral (intravenous, intramuscular) administra-
tion, yet also candidates for nose-to-brain delivery. This latter
route not only delivers peptides to the brain via the olfactory
pathway, but it can lead to high plasma levels, mimicking the
pharmacokinetic profile achieved after intravenous adminis-
tration and potentially resulting inmore peptide accumulating
in the brain if it is brain permeable. Thus, it was critical to
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assess in vitro BBB permeability to decide which of the lipopep-
tides should be taken further into preclinical development.
Nose-to-brain delivery strategies might be preferred to treat
a chronic condition like AD, permitting patient self-
administration without the need for complicated training.
Advances in nasal devices and formulations will probably pro-
duce very stable formulations, and that can ensure 1–2% of
the nasally administered dose reaches the brain (1,3).
The permeability of mouse/human Lau-PTEN-PDZ pep-
tides is similar to that reported for brain permeable peptides
like Angiopep-2 based on the Kunitz domain of aprotinin
(Papp (cm/s) = 8.69 ± 1.53 × 0−6 [36]). This domain is brain
permeable in vitro and in vivo, on its own, as a drug conjugate or
as a peptide-functionalized nanomedicine that can be loaded
with a therapeutic cargo. Current permeability values indicate
that at financially viable doses, 0.2% of an intravenously
injected dose can reach the brain. This value may be further
enhanced if the nasal route is selected for delivery with an
appropriate device (3). The nasal route by-passes the BBB
and delivers peptides straight into the brain. Through this
route, the peptides can elicit blood levels with clearance sim-
ilar to that observed after intravenous administration. Thus,
the nasal route might potentiate the accumulation of the brain
permeable peptide with a long half-life in circulation, resulting
in brain levels that reach 1–2% of the dose administered. The
diffusion of therapeutic peptides (<10 kDa) into the extracel-
lular brain parenchyma, such as that described here, is not
restricted significantly when compared to that of larger neuro-
trophic factors like neurotrophins, PDGF (platelet-derived
growth factor) and CNTF (ciliary neurotrophic factor) which
approach the dimensions of the extracellular space (15–20 nm
in diameter) (39). The clearance of the peptides in the target
organ is also an essential feature, as this will permit the deg-
radation of the therapeutic peptides into elements that are
naturally present in the brain parenchyma (40).
As such, these peptides may serve as potential candidates
for pharmacological interventions in conditions of Aß over-
load, and by saturating PTEN-PDZ interaction sites, we can
effectively protect synapses against Aβ, preventing the cogni-
tive deterioration triggered by Aβ overload.
CONCLUSIONS
We show here that PTEN-PDZ lipopeptides may represent a
feasible clinical strategy for the symptomatic treatment of AD
patients. The interactions of therapeutic peptides differ from
those of small molecules, and their toxicity and immunogenic-
ity are limited, making them ideal candidates to treat brain
diseases. Lipidized peptides have a longer half-life in circula-
tion and enhanced permeability across biological barriers.
Examining different analogs of PTEN-PDZ peptides, we have
identified the optimal lipidic tail for stability and permeability
across difficult biological barriers like the BBB, maintaining
low cytotoxicity. We identified the mouse Lau-PTEN-PDZ as
the right candidate for further development as a minimally
invasive medicine for self-administration via the nasal, intra-
muscular, or subcutaneous routes in order to prevent or delay
memory defects in the early phases of AD.
Table II Permeability of the
Compounds Across an In Vitro 2D
Human BBB Model
Compound Experiment 1 Experiment 2
Papp0-4h (×10
−6 cm s−1) Papp0-4h (×10
−6 cm s−1)
Human Lau-PTEN-PDZ 5.57± 0.29
Mouse Lau-PTEN-PDZ 6.28± 1.85
Human Myr-PTEN-PDZ 3.77± 0.39
Mouse Myr-PTEN-PDZ 2.63± 0.08
FITC-Dextran (3–5 kDa) 6.91± 0.30
Diazepam 19.07± 0.58 18.90± 0.86
Table III Pharmacological Profiles of the Peptide Drug Candidates
Factors Human Lau-PTEN-PDZ Mouse Lau- PTEN-PDZ Human Myr-PTEN-PDZ Mouse Myr-PTEN-PDZ
Simulated intestinal fluid stability +++ ++ +++ +++++
Liver homogenate stability ++ ++ ++ +++++
Plasma stability (mouse, 50% v/v) ++ +++++ ++ +++
Brain homogenate stability +++ +++ ++++ +++
In vitro BBB permeability ++++ ++++ ++ +
Cell viability +++++ +++++ +++++ +
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